Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections

Flurithromycin Ethylsuccinat in der Therapie bakterieller Infektionen der tiefen Atemwege

  • 39 Accesses

  • 5 Citations

Summary

Efficacy and tolerability of flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18–87 years) were treates with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections.

Zusammenfassung

Die Wirksamkeit und Verträglichkeit von Flurithromycin Ethylsuccinat wurde bei Patienten mit Infektionen der tiefen Atemwege geprüft. 110 Patienten (38 Frauen, 72 Männer, im Alter von 18–87 Jahren) erhielten zweimal täglich eine Tablette Flurithromycin Ethylsuccinat zu 375 mg. Insgesamt wurden 62,9% der Patienten klinisch geheilt, 19% gebessert. Die Rate an befriedigendem klinischen Ansprechen lag somit bei 81,9%. Bei den meisten Patienten ging die Sputumproduktion zurück. Bei 47% hatte die Sputumproduktion nach Behandlungsende aufgehört (nur bei einem Patienten bestand zu Therapiebeginn keine Sputumproduktion). Purulentes oder mukopurulentes Sputum bestand vor Behandlung bei 80% und nach Behandlng bei 20% der Patienten. Bei 72 Patienten war eine bakteriologische Befundung möglich. In 80,2% der Fälle wurde der Erreger eliminiert. Bei acht der 110 behandelten Patienten traten Nebenwirkungen auf, die meist den Gastrointestinaltrakt betrafen. In einem Fall mußte die Behandlung abgebrochen werden. Diese Ergebnisse zeigen, daß Flurithromycin Ethylsuccinat ein wirksames und sicheres Medikament für die Behandlung tiefer Atemwegsinfektionen ist.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Gialdroni-Grassi, G., Alesina, R., Bersani, C., Ferrara, A., Fietta, A., Peona, V. In vitro activity of flurithromycin, a novel macrolide antibiotic. Chemioterapia 5 (1986) 117–184.

  2. 2.

    Mattina, R., Raimondi, A., Bellotti, M. G., Casacci, F. In vitro determination of the anibacterial activity of a new antibiotic derivative: flurithromycin. Farmaci Terapia III (1986) 88–90.

  3. 3.

    Zanuso, G., Toscano, L., Pezzali, R., Seghetti, E.: (8S)-8-Fluoroery-thromycin A: a noval macrolide with increased acid stability. Synthesis and biologica activity. 13th Int. Congress Chemother., Vienna, 28th August-2nd September 1983, part 107, abstract 12.

  4. 4.

    Ferrara, A. M., Lepore, A. M., Bonfanti, C., Gialdroni-Grassi, G.: Pharmacokinetics of flurithromycin ethylsuccinate. In: Recent Advances in Chemotherapy, Proceedings of the 17th Int. Congress of Chemother., Berlin 1991, Futuramed Publishers, 1992, pp. 2284–2285.

  5. 5.

    Galioto, G. B., Mevio, E., Galioto, P., Zanuso, G., Lepore, A. M. Concentrations of flurithromycin in serum and tonsils. Int. J. Clin. Pharmacol. Ther. Toxicol. 27 (1989) 126–128.

  6. 6.

    Mevio, E., Galioto, G. B., Bulzomi', A. G., Ferrara, A. M., Tonon, G. C.: Pharmacokinetics of flurithromycin ethylsuccinate in respiratory tract. In: Recent Advances in Chemotherapy, Proceedings of the 17th Int. Congress of Chemother., Berlin 1991, Futuramed Publishers, 1992, pp. 518–519.

  7. 7.

    Stefani, S., Furneri, P. M., Pellegrino, M. B., Nicoletti, G., Russo, G. Activity of flurithromycin against some bacterial strains. Farmaci Terapia III (1986) 91–94.

  8. 8.

    Fietta, A., Boeri, P., Colombo, M. L., Merlini, C., Gialdroni-Grassi, G. Uptake of flurithromycin by human polymorphonuclear phagocytes: partial characterization of the entry mechanism. Chemotherapy 38 (1992) 443–450.

  9. 9.

    Fietta, A., Boeri, P., Colombo, M. L., Merlini, C., Gialdroni-Grassi, G. Bioactivity of flurithromycin and other macrolides against intracellular suceptible staphylococci. Chemotherapy 39 (1993) 48–54.

  10. 10.

    Climax, J., Rice, K., Northcutt, V.: Efficacy and safety of clarithromycin in the treatment of lower respiratory tract infections. 4th International Congress of Infectious Diseases, Montreal July 1990, abstract 437.

  11. 11.

    Schoenwald, S., Gunjaca, M., Kolancny-Babic, L., Car, V., Gosev, M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25 (suppl. A) (1990) 123–126.

  12. 12.

    Biermann, C., Loken, A., Riise, R. Comparison of spiramycin and doyscycline in the treatment of lower respiratory infections in general practice. J. Antimicrob. Chemother. 22 (suppl. B) (1988) 155–158.

  13. 13.

    De Vlieger, A., Druart, M., Everaert, L., Puttemans, M.: Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. 17th Int. Congress Chemother., Berlin 1991, abstract 757.

  14. 14.

    Muir, J. F., Guerin, J. C., Lebeau, B., Leophonte, P., Taytard, A. Antibiothérapie dans les poussées de surinfection de bronchite chronique. Etude comparative en double aveugle de la doxycycline et de la josamycine. Méd. Mal. Infect. 16 (1986) 626–630.

  15. 13.

    Carbon, C., Salord, J. C. Comparison de deux antibiotique, cefactlor et josamycine, dans le traitement des bronchites aigues de l'adulte. Gazette Méd. Fr. 91 (1984) 33–36.

  16. 16.

    Lousbergh, D., Jochems, G., Everaert, L., Puttemans, M.: Roxithromcycin versus amoxicillin plus calvulanic acid in the treatment of respiratory tract infections. 17th Int. Congress Chemother., Berlin 1991, abstract 770.

  17. 17.

    Dautzenberg, B., Scheimberg, A., Brambilla, C., Camus, P., Godard, P., Guerin, J. C., Touchais, E., Wallaert, B.: Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections. 17th Int. Congress Chemother., Berlin June 23–28, 1991, abstract 755.

  18. 18.

    Balmes, B., Clerc, G., Dupont, B., Labram, C., Pariente, R., Poirier, R. Comparative study of azithromycin and amoxycillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 437–439.

  19. 19.

    Gialdroni-Grassi, G., Grassi, C. Lower respiratory tract infections: (II) parenchymal infections. In:Bryskier, A. J., Butzler, J. P., Neu, H. C., Tulkens, P. M. (eds.), Macrolides. Chemistry, pharmacology and clinical uses. Arnette, SA., Paris 1993, pp. 535–550.

  20. 20.

    Periti, P., Mazzei, T., Mini, E., Novelli, A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23 (1992) 106–131.

Download references

Author information

Correspondence to Prof. Giulinana Gialdroni-Grassi M.D..

Additional information

Supported by Pierrel S. p. A.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bariffi, F., Clini, V., Ginesu, F. et al. Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections. Infection 22, 226–230 (1994). https://doi.org/10.1007/BF01716716

Download citation

Keywords

  • Lower Respiratory Tract
  • Lower Respiratory Tract Infection
  • Clinical Cure
  • Clinical Response Rate
  • Clinical Cure Rate